David S. Boyer, MD

David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies.

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes.

Breakthrough suprachoroidal injection technique offers promising treatment for diabetic retinopathy, reducing visual threatening complications from 37% to 4% with minimal inflammation and office-based procedure.

Investigational pipeline provides promise for an unmet need.